CHICAGO / Dec 01, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) today unveiled the Allia™ Moveoi, an image guiding solution designed to enhance mobility and flexibility and redefine the way clinicians deliver care in the interventional suite. This new Allia platform features a slim, compact, cable-free C-arm, allowing full movement and patient access, while aiming to deliver outstanding image quality. To help care teams work with ease, Allia Moveo features a wide-bore C-arm designed to enable cone beam computed tomography (CBCT) that accommodates a diverse patient population, an ergonomic design and AI-powered tools intended to provide a seamless workflow, offering patients a smooth, more personalized procedure.
“As demand for minimally invasive procedures continues to increase, clinicians are navigating greater complexities and volume, and need technology that keeps pace to enhance precision, simplify workflows, and support efficient care delivery,” said Philip Rackliffe, President and CEO, Advanced Visualization Solutions (AVS) at GE HealthCare. “Allia Moveo aims to set a new standard in interventional care, reduce barriers, and anticipate clinical needs, with the goal of empowering clinicians to deliver optimal patient outcomes with comfort and confidence.”
Clinicians perform nearly half of interventional procedures from working positions where they struggle with limited access to essential controls, displays, and interfaces.ii The unique design of Allia Moveo aims to ensure full access to the patient during both simple and complex procedures and includes thoughtful placement of motion controls—comfortably accessible from nearly any position—so clinicians can focus on what matters most: the procedure and the patient. These comfort-enhancing features also extend to patients, who may benefit from the wide bore and effortless table panning, which is designed to provide a smooth experience regardless of weight or body size.
In addition, Allia Moveo includes new features designed to enhance efficiency, like SmartMove, which allows the clinician to move the C-arm away from the patient whenever needed and return it to its original position at the press of a button, developed to minimize setup time and workflow interruptions. Artificial intelligence and augmented guidance tools also support advanced workflow with the goal of enabling greater precision. Like other Allia IGS systems, Allia Moveo is intended to sit at the center of the interventional ecosystem and supports multi-modality integrations across a wide range of imaging and diagnostic technologies that enable care teams to tailor their environment to the unique needs of each procedure.
“Allia Moveo is more than a new interventional system - it represents our boldest innovations yet, designed with intention and shaped by years of collaboration with interventionalists and surgeons,” said Jyoti Gera, Chief Executive Officer, CardioVascular and Interventional Solutions, AVS at GE HealthCare. “Created for and by clinicians, it is built to deliver agility, flexibility, and a reimagined workflow aimed at unlocking new levels of ease, efficiency, and precision care.”
Allia Moveo is currently FDA 510(k) pending. This product may not be available in all regions, contact your GE HealthCare sales representative for more information. To learn more about GE HealthCare’s Allia IGS platform, visit booth #7334 at RSNA, explore the press kit, or the RSNA 2025 events page.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
i 510(k) pending with the U.S. FDA. Not available for sale in the US. Not CE Marked.
ii According to GE HealthCare sponsored blind survey conducted with 180 interventional cardiologists, interventional radiologists, and vascular surgeons in the U.S. and Europe.
| Last Trade: | US$83.59 |
| Daily Change: | 3.37 4.20 |
| Daily Volume: | 4,779,563 |
| Market Cap: | US$38.080B |
December 03, 2025 December 03, 2025 December 02, 2025 November 30, 2025 November 30, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load